News >

FDA Accepts sNDA for Avatrombopag in ITP

Kristi Rosa
Published: Thursday, Nov 08, 2018

The FDA has accepted a supplemental new drug application (sNDA) for review for avatrombopag (Doptelet) as a treatment for patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to prior treatment, according to Dova Pharmaceuticals, the developer of the second-generation, oral thrombopoietin receptor agonist.1

Avatrombopag was initially approved by the FDA as a treatment for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.

References

  1. Dova Pharmaceuticals, Inc. Dova Pharmaceuticals announces FDA acceptance of supplemental new drug application for DOPTELET (avatrombopag) for the treatment of chronic immune thrombocytopenia (ITP). Published November 5, 2018. https://bit.ly/2D5WejX. Accessed November 8, 2018.
  2. Jurczak W, Chonjnowski K, Mayer J, et al. Phase 3 randomization study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia [published online September 7, 2018]. Br J Haematol. doi: 10.1111/bjh.15573.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x